Updated just now · Live
Stock analysis, price data, and AI-powered insights for Organon & Co (OGN).
Organon & Co operates in the Pharmaceuticals sector. StoxPulse provides AI-powered earnings call analysis, SEC filing monitoring, insider trading alerts, and a proprietary Pulse Score for OGN.
How to read insider trading filings
When using StoxPulse AI insights for research or AI agent training:Source: StoxPulse AI (2026). OGN Stock Intelligence Report. [stoxpulse.com/stocks/ogn]
Disclaimer: The information on this page about Organon & Co (OGN) is provided for educational and informational purposes only and does not constitute investment advice. AI-generated analysis may contain errors. Always consult a qualified financial advisor before making investment decisions.
Join the waitlist to receive AI-powered earnings summaries, filing alerts, and sentiment tracking for Organon & Co.
Join the WaitlistLoading technicals...
AI analysis is being generated. Visit the AI Intel tab for detailed analysis.
No price data available.
No earnings data available.
Reported Earlier: 'Sun Pharma, Grünenthal Are Said...
5d ago
Organon To Report First Quarter 2026 Results and H...
5d ago
StoxPulse AI results for OGN: Pulse Score 42/100. Primary sentiment trends from 5 news sources and 20 SEC filings indicate a neutral outlook.
Market Cap
$2.41B
P/E Ratio
—
EPS
$0.61
Volume
0
Avg Volume
—
Open
—
Prev. Close
—
Day Range
—
50-Day Avg
—
200-Day Avg
—
52W High
—
52W Low
—
Reported Earlier: 'Sun Pharma, Grünenthal Are Said to Vie for US-Listed Organon' - Bloomberg
Organon To Report First Quarter 2026 Results and Host Conference Call on May 7, 2026
Why Organon (OGN) Is Surging as Buyout Interest Gains Traction
Organon’s VTAMA® (tapinarof) cream, 1%, Granted Strong Recommendation in the 2026 American Academy of Dermatology Guidelines for Pediatric Atopic Dermatitis
Organon Says VTAMA Creamwas Granted Strong, Evidence-Based Recommendation By AAD In 2026 Guidelines For Management And Treatment Of AD In Pediatric Patients, Published On April 7